Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of a New Formulation of Euvichol in Healthy Individuals
NCT02502331Phase 3Unknown
- Sponsor
- International Vaccine Institute
- Start
- Mar 2016
- Primary completion
- Jun 2016
01
Overview
Phase 3, randomised, single-blind trial in cholera (2 arms), sponsored by International Vaccine Institute. Primary endpoints: Geometric Mean Titer of Vibriocidal antibodies against Inaba serogroup O1 at 28 days, Geometric Mean Titer of Vibriocidal antibodies against Ogawa serogroup O1 at 28 days and 1 more. Status: unknown.
02
Conditions
cholera
Beyond the preview
Go deeper on NCT02502331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502331.